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Background: Many human cancer cells express filamin A (FLNA), an actin-binding structural protein that interacts
with a diverse set of cell signaling proteins, but little is known about the biological importance of FLNA in tumor
development. FLNA is also expressed in endothelial cells, which may be important for tumor angiogenesis. In this
study, we defined the impact of targeting Flna in cancer and endothelial cells on the development of tumors
in vivo and on the proliferation of fibroblasts in vitro.
Methods: First, we used a Cre-adenovirus to simultaneously activate the expression of oncogenic K-RAS and
inactivate the expression of Flna in the lung and in fibroblasts. Second, we subcutaneously injected mouse
fibrosarcoma cells into mice lacking Flna in endothelial cells.
Results: Knockout of Flna significantly reduced K-RAS–induced lung tumor formation and the proliferation of
oncogenic K-RAS–expressing fibroblasts, and attenuated the activation of the downstream signaling molecules ERK
and AKT. Genetic deletion of endothelial FLNA in mice did not impact cardiovascular development; however,
knockout of Flna in endothelial cells reduced subcutaneous fibrosarcoma growth and vascularity within tumors.
Conclusions: We conclude that FLNA is important for lung tumor growth and that endothelial Flna impacts local
tumor growth. The data shed new light on the biological importance of FLNA and suggest that targeting this
protein might be useful in cancer therapeutics.
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Filamins are large actin-binding proteins that stabilize
delicate three-dimensional actin networks and link them to
cellular membranes during cell movements [1]. Filamins
crosslink cortical filamentous actin into a dynamic orthog-
onal network and thereby confer membrane integrity and
protection against mechanical stress. In addition to actin,
filamins bind to numerous other proteins such as trans-
membrane receptors and signaling molecules and pro-
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reproduction in any medium, provided the orbehaviors [2]. Although filamins are classically known as
cytoplasmic structural proteins, recent studies suggest that
filamins are emerged as essential scaffolding proteins that
play roles in cell signaling [2]. In addition, filamins interact
with transcriptional factors to regulate their function and
become members of transcriptional complex in the nucleus
[2]. There are three members of the filamin family, filamin
A (FLNA), filamin B (FLNB) and filamin C (FLNC). Both
human FLNA and mouse filamin A (Flna) genes are located
on the X chromosome. During embryogenesis as well as in
adults, FLNA is the most abundant isoform, is ubiquitously
expressed throughout the body and appears to be the major
filamin responsible for cardiovascular development.
Many studies have reported increased expression of
FLNA in human cancer tissues such as hepatic [3], breast,
and astrocytoma [4] as well as in different cancer cell linesal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of signaling pathways on both cancer and endothelial cell
motility during tumorigenesis. In addition, the RAS-
signaling pathway has attracted considerable attention as a
target for anticancer therapy because of its important role
in carcinogenesis [6]. Interestingly, in mammalian cells,
the generation of actin-based dynamic motile structures is
regulated by small GTPases of the Rho family and FLNA
interacts with these GTPases [7]. Following integrin bind-
ing to extracellular matrix ligands, small GTPases are acti-
vated, leading to actin polymerization and the formation
of lamellipodia and filopodia. Branched actin networks are
particularly important for the formation of lamellipodia
that are believed to be the actual motors that pull cells for-
ward. Filopodia originate from the pre-existing lamelli-
podial actin network that is prevented from capping and,
as a result, can elongate at the leading edge of the lamelli-
podia. Mutations in the K-RAS gene render the protein
unable to hydrolyze GTP and have been found in 20–30%
of non-small-cell lung cancers [8]. The small GTP-binding
proteins K-RAS, H-RAS and N-RAS belong to a family of
oncoproteins associated with many types of other human
cancer. The K-RAS gene is designated Kras2 in the mouse.
RAS proteins interact with a number of effector proteins
that in turn activate important signaling pathways, includ-
ing the RAF/MEK/ERK and the PI3K/PKB/AKT pathways
[8]. The complexity of the RAS signaling pathway and the
difficulty of targeting the RAS protein itself necessitate
continuous searches for additional mechanisms that regu-
late RAS-induced tumor growth.
A recent study showed that an interaction between
active RAS and FLNA is responsible for maintaining endo-
thelial barrier function [9]. Loss of the RAS-FLNA inter-
action promotes VE-Cadherin phosphorylation and
changes in downstream effectors that lead to endothelial
leakiness. Interestingly, complete Flna deficiency results in
embryonic lethality in mice due to severe cardiac struc-
tural malformations [10]. In addition, it has been reported
that breakdown of the endothelial lining could weaken the
blood vasculature, leading to vascular abnormalities [10].
Despite the many studies focusing on the expression and
function of FLNA in tumor cells, its role in endothelial
cells and cell migration, very little is known about the im-
portance of FLNA in endogenous tumor growth. In
addition, the specific role of FLNA in oncogenic angiogen-
esis has not yet been explored. In this study, we used two
different tumor models in mice to determine the role of
FLNA in K-RAS–induced lung tumor formation and the
role of endothelial FLNA during tumor growth.
Methods
Mice
All mice included in this study had a C57Bl/6 genetic
background. Male heterozygous mice containing a floxedstop codon (LSL) before the constitutively active Kras2
promoter (Kras2LSL) [11,12] were bred with female mice
homozygous for a conditional “floxed” allele of Flna
(Flnafl/fl) [10]. For further experiments, female mice expres-
sing Flnafl/fl were also bred with male transgenic mice
expressing Cre under control of the VE-Cadherin promoter,
an endothelial cell-specific promoter (The Jackson Labora-
tory, Bar Harbor, ME). Because the Flna gene is located on
the X chromosome, hemizygous male mice were designated
Flnao/fl. Mouse experiments were approved by the Research
Animal Ethics Committee at the University of
Gothenburg.
Genotyping
Genomic DNA was isolated from mouse tail biopsies.
The Flna allele was PCR amplified with forward (F)
primer 5`-TCTTCCTCTTTCAGCTGG-3`and reverse
(R) primer 5`-CACAGTCACCTGTTCCCA-3`, yielding
280-bp “floxed” and 250-bp wild-type fragments. The
Kras2LSL allele was genotyped by PCR amplification of
genomic DNA as described [13] and yielded a 600-bp
fragment. The activated Kras2G12D allele was genotyped
as described [13] and yielded 320-bp activated and 280-
bp wild-type fragments.
Inhalation of Cre-adenoviral vector
The Cre-adenovirus was prepared as a calcium-phosphate
coprecipitate and incubated for 20 min at room
temperature as described [13]. Groups of Flnao/flKras2LSL/+
(n=6) and littermate control Flnao/+Kras2LSL/+ (n=6) mice
at the age of 4–5 weeks were allowed to inhale 125 μl of
virus at a concentration of 5×107 PFU during light isoflur-
ane anesthesia as described [11]. Additionally, Flnao/fl alone
(n=7) and wild-type C57Bl/6 (n=7) male mice were
included as controls. The mice were euthanized 12 weeks
after inhalation and lungs were harvested for tumor ana-
lysis. All experimental mice were similar in body weight be-
fore and after infection with Ad-Cre at the age of 4 weeks
(11.1±0.5 g) and 16 weeks (32.7±1.1 g).
Histological analysis of lung tumors
Lungs from Flnao/+Kras2LSL/+ and Flnao/flKras2LSL/+
mice were inflated and fixed with paraformaldehyde. Each
lobe was separately embedded in paraffin as described
earlier [12]. Five sections at 200 μm intervals of lobes 3
and 5 were stained with hematoxylin and eosin (H&E).
To quantify lung tumor area, entire lung sections at 5
different levels in each lobe were captured under the
microscope at magnification × 5 prior to being viewed
with a Zeiss epifluorescence microscope. Images were
obtained and digitized (TIFF format; with a resolution
of 8 pixels/μm). H&E stained color was picked by
Biopix software (Version 2.1.3; Biopix, www.biopix.se)
according to the hue, saturation and brightness of the
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yellow color. Normal pulmonary and non-stained airway
structures were assigned with an artificial blue color. The
same program setting was applied to all images and areas
measured automatically by the software. To study the
expression of FLNA in lung tumors, sections were fixed in
4% PFA for 24 h, embedded in paraffin, sectioned to 5 μm
thickness and immunohistochemically stained using an
anti-FLNA antibody (Chemicon International) as described
previously [14]. Appropriate IgG controls and omission
of primary antibody served as negative controls to
immunohistochemistry. To quantify tumor endothelial
cell density, lungs were used for immunohistochemis-
try as described previously [15]. Sections were stained
with a primary antibody, rat monoclonal anti-CD31
(PECAM-1) (Pharmingen). Secondary FITC-conjugated
and Alex-conjugated antibodies (1:100; Molecular Probes,
Sweden) were applied. Sections were then washed and
mounted with mounting media (Dako) and analyzed using
a ZEISS Axioskop II microscope. The capillary density
within the tumors was calculated by computer in five
randomly selected areas captured from PECAM-stained
lung sections.
Isolation of mouse embryonic fibroblasts
Kras2LSL/+ male mice were bred with Flnafl/fl females.
Embryos were harvested from pregnant females at em-
bryonic day 14. Genomic DNA from embryos was geno-
typed for both Kras2LSL and Flnafl alleles. Isolation and
immortalization of mouse embryonic fibroblasts (MEF)
were performed as described [16]. Embryonic liver, intes-
tines, head and extremities were removed, the rest was
tweezed on a petri plate with trypsin-EDTA and shaken
on a rocking platform at 4°C overnight. The next day,
5 ml of prewarmed MEF medium was added, mixed by
pipetting up and down and incubated for 5 minutes.
Supernatant containing cells were collected and added to
T175 flask containing 20 ml of MEF medium, in which
DMEM was supplemented with 10% FBS, 1% penicillin/
streptomycin, 1% NEAA and 1% glutamine.
Proliferation assay
30 × 103 MEFs were seeded in triplicate in 6-well plates
and incubated in serum-free medium overnight. The
medium was then replaced with medium containing 10%
serum and the cells were trypsinized and counted at 1, 2,
3 and 4 days of observation. Results of triplicate experi-
ments are given as mean ± SD values and presented as
fold-increases normalized to day 1.
Western blotting
Equal amounts of protein from total MEF extracts were
size-fractionated on 4–12% SDS/PAGE gels (Invitrogen).
The proteins were transferred to nitrocellulose membranes,blocked with 5% milk and incubated with antibodies rec-
ognizing FLNA (Bethyl Laboratories), Actin (Sigma),
p-ERK, total ERK, p-AKT, and total AKT (Cell Signaling
Technology) as described earlier [14]. Protein bands were
visualized with a horseradish peroxidase-conjugated sec-
ondary antibody (Cell Signaling Technology) and the ECL
Western Blotting System (GE Healthcare). Images of
immunoblots were captured using a gel documentation
system (Bio-Rad, Gel Doc 2000). Protein bands from tripli-
cate experiments were analyzed by densitometry with
Quantity One 4.4.0 software (Bio-Rad).
Isolation of cardiac and pulmonary endothelial cells and
RT-PCR
Whole mouse hearts or lungs were placed in ice-cold PBS,
minced into 1 mm3 pieces and digested using 100 μg/ml
Collagenase type III (Sigma) in Hanks’ balanced salt solu-
tion (HBSS, Invitrogen) supplemented with 1% BSA and
100 U/ml DNase at 37°C for 15 min with gentle agitation
as described earlier [17]. Tissues were then gently pressed
through 100 μm and then 40 μm cell strainers (Falcon, BD
Biosciences). Cells were washed out from the strainer in
2 ml of HBSS supplemented with 1% BSA and 100 U/ml
DNase, pelleted at 200 × g for 5 min, suspended in 1.5 ml
HBSS supplemented with 1% BSA and 100 U/ml DNase,
and again pelleted and resuspended. Rat anti-CD31 (BD
Pharmingen) antibody-coated magnetic beads (Dynabeads
M-450, sheep anti-Rat IgG, Dynal) were added, and after
incubation at 4°C for 30 min with gentle agitation, pul-
monary endothelial cells were isolated with a magnetic
particle concentrator (MPC, Dynal) and washed three
times with HBSS supplemented with 1% BSA.
The purity of the isolated endothelial cells was con-
firmed by RT-PCR using primers to detect mRNA expres-
sion of mouse Pecam as a positive control and primers to
amplify the smooth muscle-specific mRNA expression of
mouse Sm22α as a negative control. Mouse primers ampli-
fying transcripts of Flna (F primer 5'-AAGCCC
TCTGCAGTTCTATGTTGA T-3' and R primer 5'-GCA
AACGTTTCAGCAGACAGGGTT-3'), 18 S (F primer 5'-
AGATCAAAACCAACCCGGTGA-3' and R primer 5'-
GGTAAGAGCATCGAGGGGGC-3'), Pecam (F primer
5'-AGGGGACCAGCTGCACATTAG G-3' and R primer
5'-AGGCCGCTTCTCTTGACCACT T-3') and SM22α
(F primer 5'-CCACACTCTATACTTTAGCTCTGCC
TCAAC-3' and R primer 5'-CAGGCTGTTCACCAA
TTTGCTCAGAAT-3') were used for RT-PCR as
described [16].
Histological analysis of hearts
Hearts were removed from adult VE-CadCre/+Flnao/+ and
VE-CadCre/+Flnao/fl mice, fixed with paraformaldehyde,
embedded in paraffin, sectioned, and stained with H&E
to study histomorphology.
Nallapalli et al. Molecular Cancer 2012, 11:50 Page 4 of 11
http://www.molecular-cancer.com/content/11/1/50Analysis of cardiac function by echocardiography
Transthoracic color Doppler echocardiography was per-
formed on isoflurane-anesthetized mice at the age of
8 weeks as described [15]. During the procedure, the mice
were maintained lightly anesthetized with an isoflurane
dose of approximately 1.2% in air using a nose mask.
Examinations were performed using a high-frequency 15-
MHz linear transducer (CL 15–7; Philip Medical System)
connected to an HDI 5000 ultrasound system (ATL; Philip
Medical System). All measurements were based on the
average of at least 3 cardiac cycles. Fractional shortening
was calculated using left ventricular (LV) end diastolic
diameter (LVEDd) and systolic diameter (LVESd) values
as (LVEDd–LVESd)/LVEDd × 100. Other measurements
of cardiac function included diastolic and systolic LV
internal diameter, diastolic posterior wall thickness, rela-
tive wall thickness, and LV mass by M-mode as described
earlier [15].
Migration assay
Migration assays were performed on lung endothelial cells
in passage 2–3. Cell migration was quantified with a modi-
fied Boyden chamber assay [16] where the ability of cells to
migrate through a micropore nitrocellulose filter (8 μm
thick, 8 μm pores in diameter) was measured. Approxi-
mately 3×104 cells were seeded in the upper chamber in
medium containing 2% FBS; the chamber was lowered into
a well containing 10% FBS. After 4 h of incubation at 37°C,
migrated cells were fixed to the filter in methanol and
stained with Giemsa. All cells that had migrated through
the filter were counted using a light microscope. Triplicates
of each sample are presented as mean±SD values.
Subcutaneous tumor cell inoculation in mice
Five-week-old VE-CadCre/+Flnao/fl and control VE-
CadCre/+Flnao/+ male mice were given subcutaneous injec-
tions of 1×106 of T241 mouse fibrosarcoma or B16 melan-
oma cells in the dorsal back region as described earlier [18].
Tumor volume was calculated by measurements of width2 ×
length×0.52. The diameter of isolated tumors was mea-
sured every second day starting one week after inoculation
and tumors were harvested before they reached a size of
1.5 cm3. Tumors were carefully resected, weighed, placed in
OCT, snap-frozen in liquid nitrogen and stored at −80°C.
The vascular network within the fibrosarcomas was visua-
lized by whole-mount immunostaining of vascular endothe-
lial cells and pericytes using anti-PECAM and anti-NG-2
antibodies, respectively, as described earlier [18].
Statistical analysis
Data are given as mean ± standard deviation (SD). Differ-
ences between experiment groups were analyzed for stat-
istical significance (P < 0.05) by two-way ANOVA or
Student’s t test.Results
Targeting Flna reduces K-RAS–induced lung tumor
development in mice
To study the role of Flna in K-RAS–induced tumor
development, we bred “floxed” conditional Flna knockout
mice (Flnafl) with mice harboring a loxP-STOP-loxP
K-RASG12D allele (Kras2LSL/+) (Figure 1A). The genotype
of offspring was confirmed by genomic PCR for Flnafl
(Figure 1B) and Kras2LSL (Figure 1C). Flna is located on the
X chromosome and we performed experiments with male
Flnao/flKras2LSL/+ and male littermate control Flnao/+
Kras2LSL/+ mice. We administered a Cre-adenovirus to
4–5-week-old mice by intranasal instillation. Cre expression
activated K-RASG12D expression in the lung of both groups
of mice and simultaneously inactivated the single copy of
Flna in Flnao/flKras2LSL/+ mice. No experimental complica-
tion such as mouse death due to adenoviral inhalation was
seen. After 12 weeks, mice were euthanized and lungs har-
vested. C57Bl/6 wild-type and Flnao/fl alone control mice
did not develop lung tumors after inhalation of Ad-Cre and
were, therefore, not further processed for histological
analysis. Both Flnao/flKras2LSL/+ and Flnao/+Kras2LSL/+ mice
developed macroscopically visible lung tumors (Figure 2A).
However, macroscopic evaluation revealed a reduced tumor
burden in Flnao/flKras2LSL/+ compared to Flnao/+Kras2LSL/+
mice. Histological examination of lung sections showed
pulmonary adenocarcinomas (Figure 2B). The tumor area
in lungs of Flnao/flKras2LSL/+ mice was reduced by 35%
compared to Flnao/+Kras2LSL/+ (Figure 2C and D,
P < 0.05; 34.1 ± 15.0% versus 52.3 ± 13.3%). Less intense
immunohistochemical expression of FLNA was
observed in Flnao/flKras2LSL/+ lung tumors compared to
Flnao/+Kras2LSL/+ lung tumors as a result of Flna deletion
in pulmonary epithelial cells after infection with Ad-Cre
(Figure 2E). There were similar numbers of vascular
structures in both groups of mice as quantified by im-
munofluorescence staining with anti-PECAM antibodies
(Figure 2F).
Flna deficiency reduces proliferation of mouse embryonic
fibroblasts
We isolated fibroblasts from Flnao/flKras2LSL/+ and Flnao/+
Kras2LSL/+ embryos and incubated them with the Cre-
adenovirus to activate K-RASG12D expression in cells of
both genotypes and simultaneously inactivate the single
Flna copy in Flnao/flKras2LSL/+ cells. The genotypes of the
resulting cells were Flnao/ΔKras2G12D/+ and Flnao/+
Kras2G12D/+ (Figure 3A and B). As expected, the prolif-
eration of Flnao/+Kras2G12D/+ cells increased com-
pared to wild-type cells due to K-RASG12D expression
(Figure 3C). However, the proliferation of Flnao/Δ
Kras2G12D/+ cells was reduced compared to Flnao/+
Kras2G12D/+ cells (Figure 3C) and this reached signifi-




































Figure 1 Strategy for inactivating the expression of FLNA and simultaneously activating the expression of K-RASG12D in mouse lungs.
(A) Schematic illustration of mouse allele, Flnafl and Kras2LSL. Numbered boxes represent exons. Infection of lungs with adenoviral vector
encoding Cre (Ad-Cre) yields a truncation of exons 2–8 of Flna and removal of LSL before constitutive activation of the Kras2 promoter. Sites for
forward (F) and reverse (R) oligonucleotide primers are indicated (arrows). (B) Genotyping of male (Flnao/fl) and female (Flna+/fl) mouse tails by
genomic PCR using F1 and R1 primers detecting Flna alleles. Higher band represents Flnafl allele. (C) Genotyping of mouse tails by genomic PCR
using F4 and R4 primers for LSL. Amplicons represent Kras2LSL.
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cell number). The total levels of both ERK and AKT
were smaller in wild-type control cells than Flnao/+
Kras2G12D/+ cells (Figure 3D, immunoblots). Compared to
Flnao/+Kras2G12D/+ cells, levels of FLNA protein in Flnao/Δ
Kras2G12D/+ cells were reduced by 74% as quantified by
Western blotting of whole-cell lysates (Figure 3D). Inter-
estingly, stead-state levels of phospho-ERK and phospho-
AKT in Flna-deficient cells were reduced by 25 and 55%,
respectively, compared to controls (Figure 3D).
Flna deficiency in endothelial cells has no apparent
impact on cardiac development and function
To define the importance of endothelial FLNA in cardio-
vascular development, we bred Flnao/flmice with mice
harboring a Cre transgene driven by the endothelial cell-
specific VE-Cadherin promoter. We isolated endothelial
cells from hearts of VE-CadCre/+Flnao/fl and littermate
control VE-CadCre/+Flnao/+ mice with PECAM-
conjugated microbeads. The purity of the endothelial cell
preparation was confirmed by the presence of Pecam
transcripts and by the absence of Sm22α transcripts.
Flna mRNA transcript and protein were essentially
eliminated in VE-CadCre/+Flnao/fl endothelial cells
(Figure 4A). To assess the impact of endothelial cell-
specific inactivation of FLNA on cardiac morphology, weperformed histological staining (Figure 4B). Additionally,
cardiac tissues with or without endothelial FLNA
(VE-CadCre/+Flnao/+ and VE-CadCre/+Flnao/fl, respect-
ively) were immunohistochemically stained (Figure 4C).
Finally, we performed echocardiography analyses to
measure the percentage of cardiac fractional shortening
(Figure 4D). These studies indicated that cardiac histo-
morphology and cardiac pump function were similar in
control VE-CadCre/+Flnao/+ and VE-CadCre/+Flnao/fl
mice. Other parameters of cardiac function were also
found to be similar between VE-CadCre/+Flnao/+ and
VE-CadCre/+Flnao/fl hearts, including left ventricular
internal diameter diastole (4.39 ± 0.50 mm versus
4.18 ± 0.26 mm, P = 0.50 at baseline and
3.64 ± 0.54 mm versus 3.57 ± 0.19 mm, P = 0.83 during
dobutamine stress), left ventricular internal diameter
systole (3.04 ± 0.76 mm versus 2.62 ± 0.50 mm, P = 0.39
at baseline and 1.96 ± 0.42 mm versus 1.68 ± 0.24 mm,
P = 0.30 during dobutamine stress), posterior diastolic
wall thickness (0.80 ± 0.11 mm versus 0.79± 0.08 mm,
P=0.8), relative diastolic wall thickness (0.18 ± 0.01 mm
versus 0.19± 0.02 mm, P=0.71), and left ventricular mass
calculated by M-mode echo (142.37± 51.66 mg versus
124.33± 22.65 mg, P=0.55). Taken together, these data
suggest that FLNA in endothelial cells is dispensable for





























Figure 2 Inactivation of Flna reduces tumor burden in a Kras2G12D-induced lung cancer in mice. (A) Photographs of lungs 12 weeks after
inhalation of adenoviral vector encoding Cre (Ad-Cre). Note the extensive tumor lesions (white areas) on the surface of lungs from Flnao/+Kras2G12D/+
male mice and the relatively normal appearance of the lungs from Flnao/flKras2G12D/+ male mice. (B) Hematoxylin & Eosin (H&E)-stained sections of
representative lesions in lungs from Flnao/+Kras2G12D/+ and Flnao/fl Kras2G12D/+ male mice. Original magnifications× 20. (C) Computer-assisted image
analysis of H&E-stained lung tumor areas (upper panels) using artificial colors (lower panels). Yellow color represents lung tumor areas, whereas blue
color indicates normal pulmonary structures and airways. Original magnifications× 5. (D) Mean± SD values of percentage of lung tumor areas from
entire lower right and left lung lobes sectioned at five different levels. Each group consisted of at least 5 mice. Student’s t test, *P<0.05. (E)
Immunohistochemical staining of Flnao/+Kras2G12D/+ and Flnao/flKras2G12D/+ lung tumor areas using an anti-FLNA antibody. Red color represents
immunohistochemical FLNA-positivity, whereas blue color indicates nuclear counterstaining. Original magnifications × 20 and×100 (insets). (F)
Immunofluorescence detecting of endothelial cells in lung tumors by an antibody against PECAM (red). Nuclear DAPI staining (blue). Original
magnifications× 20.
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the ability to support subcutaneous tumor growth
To define the ability of FLNA in endothelial cells to
support tumor growth, we bred Flnao/flmice with mice
harboring a Cre transgene driven by the endothelial cell-
specific VE-Cadherin promoter. We isolated lung endothe-
lial cell proteins from VE-CadCre/+Flnao/fl and littermate
control VE-CadCre/+Flnao/+mice with PECAM-conjugated
microbeads. This indicated that FLNA protein was essen-
tially eliminated in VE-CadCre/+Flnao/fl endothelial cells
(Figue 5A). Interestingly, the ability of Flna-deficient endo-
thelial cells to migrate was reduced by 38% compared to
control cells (224 ± 25 VE-CadCre/+ Flnao/+ cells versus
139± 36 VE-CadCre/+Flnao/fl, P<0.05) (Figure 5B). We
then subcutaneously inoculated T241 mouse fibrosarcoma
cells into VE-CadCre/+Flnao/fl and VE-CadCre/+Flnao/+mice and measured tumor volume (Figure 5C). The sub-
cutaneous tumors grew significantly slower in VE-CadCre/+
Flnao/fl compared to VE-CadCre/+Flnao/+ mice and were
0.77±0.12 cm3 (n=7) and 1.06±0.77 cm3 (n=8), respect-
ively, at 13 days after inoculation (P<0.05). Similarly,
inoculation of B16 mouse melanoma cells resulted in
reduced tumor growth. Melanoma tumor volumes in VE-
CadCre/+Flnao/fl and VE-CadCre/+Flnao/+ mice were
0.22±0.05 cm3 (n=6) and 0.32±0.09 cm3 (n=7), respect-
ively, at day 9 (P<0.05) and 0.34±0.05 cm3 and
0.47±0.12 cm3, respectively, at day 11 (P < 0.01) (data
not shown). To visualize the vascular network within
fibrosarcomas inoculated into VE-CadCre/+Flnao/fl and
VE-CadCre/+Flnao/+ mice, whole-mounted tumor tissues
were stained with antibodies detecting endothelial cells




Figure 3 Inactivation of Flna reduces proliferation of K-RASG12D–expressing primary mouse embryonic fibroblasts (MEF). (A) Genotyping
of MEF by genomic PCR using F1 and R2 primers, as indicated in Figure 1, for Flna before (left lanes) and after (right lanes) infection with
adenoviral vector encoding Cre (Ad-Cre). M, DNA ladder. (B) Genotyping of MEF by genomic PCR using F4 and R4 primers, as indicated in
Figure 1, for Kras2 after infection with Ad-Cre. Upper band represents insertion of a single loxP site after removal of LSL in the Kras2 gene
(Kras2G12D). (C) Proliferation assay of K-RAS–induced MEF with or without Flna up to 4 days. Wild-type MEF cells were included as controls. (D)
Representative immunoblots of FLNA, phosphorylated ERK (p-ERK) and AKT (p-AKT) in K-RAS–induced cells with or without Flna after infection
with Ad-Cre. Actin loadings and total ERK (t-ERK) and AKT (t-AKT) immunoblots served as internal controls. Mean± SD values of densitometric
readings of band intensities in triplicate experiments. Student’s t test, *P< 0.05, **P< 0.01.
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fibrosarcomas was significantly reduced in VE-CadCre/+
Flnao/fl mice compared to VE-CadCre/+Flnao/+ mice
(6.38±1.82×104/ μm2 versus 3.47±0.40×104/ μm2,
P=0.002) (Figure 5E, upper panel). However, the number
of pericytes (2.21±0.89×104/ μm2versus 1.56±0.16×104/
μm2) or pericyte-covered vascular areas (41±15% versus
46±10%) was not changed (Figure 5E, middle and lower
panels).
Discussions
In this study, we demonstrated that knockout of Flna
reduces K-RAS–induced lung tumor development
in vivo and reduces the proliferation of K-RASG12D–
expressing fibroblasts in vitro. The reduced fibroblast
proliferation was associated with reduced levels of acti-
vated ERK and AKT. Moreover, we showed that target-
ing Flna specifically to endothelial cells reduces their
migratory ability and retards local tumor growth.Endogenous activation of K-RASG12D in the lung
results in adenocarcinoma that originates in terminal
and respiratory bronchi or in the alveolar epithelium
[12]. Adenocarcinoma of the lung is the most common
type of lung cancer in lifelong non-smokers [19]. Studies
of human lung cancer have shown that adenocarcinoma
is the only subtype associated with RAS mutations [20].
In the Kras2LSL model, inhalation of Cre-adenoviral
vector results primarily in infection of respiratory epithe-
lial cells, where Cre deletes the “floxed” stop cassette to
activate the expression of K-RASG12D from the endogen-
ous promoter. In the Flnao/flKras2LSL/+ mice, Cre expres-
sion simultaneously inactivated Flna. Although Flna
deficiency significantly reduced lung tumor development,
it did not abolish tumors. This could conceivably be
caused by partial recombination, where the K-RAS allele
would be activated by Cre but Flna would not be inacti-
vated in every cell as reported [12,19]. We believe that
Cre-adenovirus infection in the Kras2LSL lung does not
Figure 4 Normal cardiac morphology and function in mice deficient for FLNA in vascular endothelium. (A) RT-PCR analysis of Flna and
Pecam transcripts in cardiac endothelial cells extracted from a female mouse encoding Cre under the VE-Cadherin promoter and expressing
wild-type Flna (VE-CadCre/CreFlna+/+) and from a male mouse that expresses no FLNA (VE-CadCre/+Flnao/fl). Sm22α served as a negative control to
demonstrate the purity of endothelial cell extraction from vascular smooth muscle cells and 18 S served as internal loading control. (B)
Immunohistochemical detection of FLNA in hearts. Red color represents immunohistochemical positivity and blue color indicates nuclear
counterstaining. The black arrow points to a FLNA-positive endothelial cell in VE-CadCre/CreFlnao/+ heart, whereas the white arrow indicates a
FLNA-negative endothelial cell in VE-CadCre/+Flnao/fl heart. Original magnifications × 20. (C) No histomorphological differences in adult cardiac
sections between VE-CadCre/+Flnao/+ and VE-CadCre/+Flnao/fl male mice. Hematoxylin & Eosin stain. LA; left atrium, RV; right ventricle, LV; left
ventricle. (D) No differences in percentage of cardiac fractional shortening between VE-CadCre/+Flnao/+ and VE-CadCre/+Flnao/fl male mice as
measured by cardiac ultrasound.
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alleles in endothelial cells as these cells are located at some
distance from the respiratory epithelium.
The RAS/RAF/MEK/ERK and RAS/PI3K/PTEN/AKT
signaling pathways are cascades regulated by phosphoryl-
ation and dephosphorylation by specific kinases, phos-
phatases, as well as GTP/GDP exchange proteins,
adaptor proteins and scaffolding proteins [21]. These
pathways play key roles in the proliferation of tumor
cells and growth of tumors. Therefore, inhibitors tar-
geting these pathways have many potential uses for
suppression of cancer. However, cancer therapy is
often complex as there are relatively few cancers
which proliferate in response to a single molecule
interaction which prevents them from being treated
with a monospecific drug. Therefore, new targets need to
be identified to develop more effective treatments. In this
study, we showed that cellular K-RAS–induced prolifera-
tion was reduced by Flna deficiency. The effect wasassociated with impaired activation of the RAS down-
stream effectors ERK and AKT. This finding suggests that
targeting FLNA might be considered in combined treat-
ment with established targets. The impact of Flna defi-
ciency on cellular proliferation has not been reported
in normal MEFs [10], however, we observed that
Flna-deficiency impairs proliferation of these cells
when induced by K-RAS.
What is the mechanism behind the reduced tumor
growth and proliferation in K-RAS–expressing cells?
One potential explanation is that FLNA acts as a scaf-
folding protein and is required for efficient spatial and
temporal activation of effectors in the RAS pathway and
that the absence of FLNA directly affects RAS signaling.
Another is that FLNA is involved in regulating the dy-
namics of the actin cytoskeleton and that the impact of
Flna deficiency on tumor growth reflects a more general
role for the protein in cellular structure and function. A
third, perhaps more intriguing possibility, is that the
Figure 5 Fibrosarcoma cells inoculated into mice lacking Flna in endothelial cells form smaller tumors. (A) Immunoblot of endothelial
cells extracted from VE-CadCre/+Flnao/+ and VE-CadCre/+Flnao/fl lungs. Actin loading served as internal loading. (B) Decreased percentage of
migrated VE-CadCre/+Flnao/fl endothelial cells as assayed by a modified Boyden’s chamber. Student’s t test, *P< 0.05. (C) Tumor size measurements
up to 13 days after inoculation of mouse fibrosarcoma cells into VE-CadCre/+Flnao/+ and VE-CadCre/+Flnao/fl male mice. Student’s t test, *P< 0.05. (D)
Representative micrographs of vascular networks in VE-CadCre/+Flnao/+ and VE-CadCre/+Flnao/fl fibrosarcomas. Red color represents PECAM-positive
endothelial cells, whereas blue color identifies NG-2–positive pericytes. Original magnifications× 20. (E) Quantification of microvascular and pericyte
areas, and percentage of pericyte-covered vascular structures within tumors. Student’s t test, *P<0.05.
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regulate gene transcription in the nucleus [22]. Over the
next few years, studies will likely shed light on these dif-
ferent possibilities.
Because FLNA has been shown to be important in vas-
cular cells [10,23], we were interested in defining the
impact of Flna deficiency on both normal and tumor
endothelial cells. Interestingly, mice lacking Flna in
endothelial cells had no apparent phenotypes. Cardiac
development and function appeared to be normal andvascular integrity was unaffected. This finding was sur-
prising for several reasons. First, Flna-deficient mice
showed prominent cardiovascular abnormalities as well
as extensive defects in cell–cell junctions that were par-
ticularly prominent in vascular endothelial cells [10].
And second, multiple functions of FLNA in endothelial
cells have recently been reported including caveolae
internalization and trafficking [24] and chemotaxis [25].
Interestingly, a crucial role for another filamin, FLNB, in
endothelial cell migration and in the angiogenic process
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filamin genes are highly conserved and the filamin pro-
teins exhibit high amino acid identity and can also form
heterodimers [2], it is likely that FLNA and FLNB have
both unique and overlapping roles in the vascular endo-
thelium. Regardless, our findings suggest that FLNA
might not be as important for endothelial cell function
as had previously been appreciated. We did, however,
observe reduced migration of Flna-deficient endothelial
cells. Moreover, we found that fibrosarcoma and melan-
oma tumor growth under the skin of mice lacking Flna
in endothelial cells was reduced. As FLNA was specific-
ally deficient in vascular endothelial cells, we observed a
significantly reduced number of vascular endothelial
cells, but not pericytes. This result suggests that endo-
thelial FLNA may be important in tumor angiogenesis.
In summary, this study provides new insight into the
biology of FLNA and suggests that in addition to its clas-
sically known cytoskeletal function, the protein also plays
an important role in the activation of ERK and AKT sig-
naling pathways during K-RAS–induced transformation.
Additionally, mice lacking Flna in endothelial cells devel-
oped smaller tumors. Finally, the experimental approach
described here should be useful for dissecting the in vivo
importance of Flna in other cancers and in tumor and
physiological angiogenesis.
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